Answers are grounded in this paper and cite their sources.
Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, is characterized by its genomic heterogeneity and high risk of recurrence after nephrectomy. While the majority of ccRCC tumors harbor somatic mutations in VHL tumor suppressor gene (VHLmut), approximately 20–25% lack VHL mutations (VHLwt), and may exhibit different progression patterns. VHLwt tumors remain significantly underrepresented in genomic studies. Our objective was to compare prognostic significance of somatic mutations in ccRCC-associated genes between patients with VHLmut and VHLwt tumors. We analyzed genomic and clinical data of 914 ccRCC patients (720 VHLmut and 194 VHLwt) from the Cancer Genomics of the Kidney (CAGEKID) cohort. Prognostic impacts of individual and co-occurring mutations in 12 RCC-related genes as well as chromosomal copy number variations (CNVs), associated with survival, were evaluated in VHLmut and VHLwt groups through survival analyses. Findings were compared between the two groups. Prognostic significance of somatic mutations in BAP1, SETD2 and PBRM1, is dependent on VHL mutational status. Co-occurring mutations in PBRM1 and SETD2 were significantly associated with poorer clinical outcomes in VHLmut tumors, but not in VHLwt tumors. TP53 mutations were associated with poorer survival in VHLwt tumors. The differing prognostic effects of somatic mutations by VHL status suggest distinct underlying mechanisms of disease progression in VHLwt ccRCCs, highlighting the need to consider VHLwt separately from VHLmut tumors in prognostic and predictive models. Further investigations of these observations in independent cohorts are warranted.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: